Celiac Disease – Pipeline Review, H2 2012
出 版 商：Global Markets Direct
出版日期：2012/08/31
頁 數：68頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Celiac Disease – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Celiac Disease - Pipeline Review, H2 2012', provides an overview of the Celiac Disease therapeutic pipeline. This report provides information on the therapeutic development for Celiac Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Celiac Disease. 'Celiac Disease - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Celiac Disease.
- A review of the Celiac Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Celiac Disease pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Celiac Disease.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Celiac Disease pipeline depth and focus of Celiac Disease therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Summary
Global Markets Direct’s, 'Celiac Disease - Pipeline Review, H2 2012', provides an overview of the Celiac Disease therapeutic pipeline. This report provides information on the therapeutic development for Celiac Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Celiac Disease. 'Celiac Disease - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Celiac Disease.
- A review of the Celiac Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Celiac Disease pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Celiac Disease.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Celiac Disease pipeline depth and focus of Celiac Disease therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Celiac Disease Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Celiac Disease 8
Celiac Disease Therapeutics under Development by Companies 10
Celiac Disease Therapeutics under Investigation by Universities/Institutes 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Discovery and Pre-Clinical Stage Products 15
Comparative Analysis 15
Celiac Disease Therapeutics – Products under Development by Companies 16
Celiac Disease Therapeutics – Products under Investigation by Universities/Institutes 17
Companies Involved in Celiac Disease Therapeutics Development 18
BioLineRx, Ltd. 18
Alba Therapeutics Corporation 19
ActogeniX NV 20
Artielle ImmunoTherapeutics, Inc. 21
Altor BioScience Corporation 22
Alvine Pharmaceuticals, Inc. 23
Avaxia Biologics, Inc. 24
Provid Pharmaceuticals, Inc. 25
FunZyme BioTechnologies S.A. 26
Celiac Disease – Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 33
Nexvax2 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ActoBiotic For Celiac Disease - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
ALT-836 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
larazotide - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Necator Americanus - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 40
Recombinant T Cell Receptor Ligands For Celiac Disease - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
ALV003 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Transglutaminase-2 Inhibitors - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
AVX-176 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
ZED-101 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
2nd Generation Proteases - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
tTG2 Inhibitors - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
HLA-DQ2 Blockers - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
BL-7010 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Nexvax3 Therapy - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Interleukin-27 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Drug Targeting DQ2/DQ8 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Celiac Disease Therapeutics – Drug Profile Updates 54
Celiac Disease Therapeutics - Dormant Products 58
Celiac Disease – Product Development Milestones 59
Featured News & Press Releases 59
May 22, 2012: Alvine Presents Phase IIa Trial Results Of ALV003 In Celiac Disease Patients At 2012 Digestive Diseases Week Meeting 59
May 01, 2012: Alba Gains Exclusive Rights To Patient Reported Outcome Questionnaire For Patients With Celiac Disease 60
Feb 21, 2012: BioLineRx Announces Publication Of Pre-Clinical Results Demonstrating Efficacy Of BL-7010 In Reducing Gluten Toxicity 60
Jan 11, 2012: Microtest Laboratories To Manufacture ImmusanT's Nexvax2 Immunotherapeutic Vaccine For Expected Clinical Trial 61
Oct 24, 2011: Alvine Pharmaceuticals Presents Additional Efficacy Data From Phase IIa Trial of ALV003 in Celiac Disease Patients 61
Oct 11, 2011: Alvine Pharmaceuticals Announces Positive Results From Phase IIa Trial Of ALV003 In Celiac Disease Patients 63
Sep 22, 2011: Alvine Pharmaceuticals Announces Upcoming Presentation Of Phase IIa ALV003 Data In Patients With Celiac Disease 64
May 09, 2011: ImmusanT Reports Positive Results From Nexvax2 Phase I Study In Celiac Disease 64
Mar 15, 2011: ImmusanT Seeks To Restore Tolerance To Gluten In Celiac Disease With Immunotherapy 65
Nov 02, 2010: Alvine Pharmaceuticals’ ALV003 Named A Top 10 Inflammatory/Autoimmune Project To Watch By Windhover 66
Appendix 67
Methodology 67
Coverage 67
Secondary Research 67
Primary Research 67
Expert Panel Validation 67
Contact Us 68
Disclaimer 68
List of Tables
Number of Products Under Development for Celiac Disease, H2 2012 8
Products under Development for Celiac Disease – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Early Clinical Stage Development, H2 2012 14
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 17
BioLineRx, Ltd., H2 2012 18
Alba Therapeutics Corporation, H2 2012 19
ActogeniX NV, H2 2012 20
Artielle ImmunoTherapeutics, Inc., H2 2012 21
Altor BioScience Corporation, H2 2012 22
Alvine Pharmaceuticals, Inc., H2 2012 23
Avaxia Biologics, Inc., H2 2012 24
Provid Pharmaceuticals, Inc., H2 2012 25
FunZyme BioTechnologies S.A., H2 2012 26
Assessment by Monotherapy Products, H2 2012 27
Assessment by Stage and Route of Administration, H2 2012 29
Assessment by Stage and Molecule Type, H2 2012 32
Celiac Disease Therapeutics – Drug Profile Updates 54
Celiac Disease Therapeutics – Dormant Products 58
List of Figures
Number of Products under Development for Celiac Disease, H2 2012 8
Products under Development for Celiac Disease – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Early Clinical Stage Products, H2 2012 14
Discovery and Pre-Clinical Stage Products, H2 2012 15
Assessment by Monotherapy Products, H2 2012 27
Assessment by Route of Administration, H2 2012 28
Assessment by Stage and Route of Administration, H2 2012 29
Assessment by Molecule Type, H2 2012 30
Assessment by Stage and Molecule Type, H2 2012 31
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Celiac Disease Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Celiac Disease 8
Celiac Disease Therapeutics under Development by Companies 10
Celiac Disease Therapeutics under Investigation by Universities/Institutes 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Discovery and Pre-Clinical Stage Products 15
Comparative Analysis 15
Celiac Disease Therapeutics – Products under Development by Companies 16
Celiac Disease Therapeutics – Products under Investigation by Universities/Institutes 17
Companies Involved in Celiac Disease Therapeutics Development 18
BioLineRx, Ltd. 18
Alba Therapeutics Corporation 19
ActogeniX NV 20
Artielle ImmunoTherapeutics, Inc. 21
Altor BioScience Corporation 22
Alvine Pharmaceuticals, Inc. 23
Avaxia Biologics, Inc. 24
Provid Pharmaceuticals, Inc. 25
FunZyme BioTechnologies S.A. 26
Celiac Disease – Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 33
Nexvax2 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ActoBiotic For Celiac Disease - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
ALT-836 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
larazotide - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Necator Americanus - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 40
Recombinant T Cell Receptor Ligands For Celiac Disease - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
ALV003 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Transglutaminase-2 Inhibitors - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
AVX-176 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
ZED-101 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
2nd Generation Proteases - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
tTG2 Inhibitors - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
HLA-DQ2 Blockers - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
BL-7010 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Nexvax3 Therapy - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Interleukin-27 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Drug Targeting DQ2/DQ8 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Celiac Disease Therapeutics – Drug Profile Updates 54
Celiac Disease Therapeutics - Dormant Products 58
Celiac Disease – Product Development Milestones 59
Featured News & Press Releases 59
May 22, 2012: Alvine Presents Phase IIa Trial Results Of ALV003 In Celiac Disease Patients At 2012 Digestive Diseases Week Meeting 59
May 01, 2012: Alba Gains Exclusive Rights To Patient Reported Outcome Questionnaire For Patients With Celiac Disease 60
Feb 21, 2012: BioLineRx Announces Publication Of Pre-Clinical Results Demonstrating Efficacy Of BL-7010 In Reducing Gluten Toxicity 60
Jan 11, 2012: Microtest Laboratories To Manufacture ImmusanT's Nexvax2 Immunotherapeutic Vaccine For Expected Clinical Trial 61
Oct 24, 2011: Alvine Pharmaceuticals Presents Additional Efficacy Data From Phase IIa Trial of ALV003 in Celiac Disease Patients 61
Oct 11, 2011: Alvine Pharmaceuticals Announces Positive Results From Phase IIa Trial Of ALV003 In Celiac Disease Patients 63
Sep 22, 2011: Alvine Pharmaceuticals Announces Upcoming Presentation Of Phase IIa ALV003 Data In Patients With Celiac Disease 64
May 09, 2011: ImmusanT Reports Positive Results From Nexvax2 Phase I Study In Celiac Disease 64
Mar 15, 2011: ImmusanT Seeks To Restore Tolerance To Gluten In Celiac Disease With Immunotherapy 65
Nov 02, 2010: Alvine Pharmaceuticals’ ALV003 Named A Top 10 Inflammatory/Autoimmune Project To Watch By Windhover 66
Appendix 67
Methodology 67
Coverage 67
Secondary Research 67
Primary Research 67
Expert Panel Validation 67
Contact Us 68
Disclaimer 68
List of Tables
Number of Products Under Development for Celiac Disease, H2 2012 8
Products under Development for Celiac Disease – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Early Clinical Stage Development, H2 2012 14
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 17
BioLineRx, Ltd., H2 2012 18
Alba Therapeutics Corporation, H2 2012 19
ActogeniX NV, H2 2012 20
Artielle ImmunoTherapeutics, Inc., H2 2012 21
Altor BioScience Corporation, H2 2012 22
Alvine Pharmaceuticals, Inc., H2 2012 23
Avaxia Biologics, Inc., H2 2012 24
Provid Pharmaceuticals, Inc., H2 2012 25
FunZyme BioTechnologies S.A., H2 2012 26
Assessment by Monotherapy Products, H2 2012 27
Assessment by Stage and Route of Administration, H2 2012 29
Assessment by Stage and Molecule Type, H2 2012 32
Celiac Disease Therapeutics – Drug Profile Updates 54
Celiac Disease Therapeutics – Dormant Products 58
List of Figures
Number of Products under Development for Celiac Disease, H2 2012 8
Products under Development for Celiac Disease – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Early Clinical Stage Products, H2 2012 14
Discovery and Pre-Clinical Stage Products, H2 2012 15
Assessment by Monotherapy Products, H2 2012 27
Assessment by Route of Administration, H2 2012 28
Assessment by Stage and Route of Administration, H2 2012 29
Assessment by Molecule Type, H2 2012 30
Assessment by Stage and Molecule Type, H2 2012 31
